Genetics of Mucopolysaccharidosis Type I Clinical Presentation
- Author: Maryam Banikazemi, MD; Chief Editor: Bruce Buehler, MD more...
History
Historically, mucopolysaccharidosis type I (MPS I) has been broadly categorized into Scheie syndrome (MPS IS), Hurler-Scheie syndrome (MPS IHS), and Hurler syndrome (MPS IH), representing clinical phenotypes ranging from least severe to most severe. These classifications are arbitrary categorizations of points on a spectrum of patient phenotypes.
Physical
Clinical manifestations of mucopolysaccharidosis type I (MPS I) show a chronic multisystemic and progressive course.[3] The disease is highly heterogeneous, spanning a spectrum of severity. Children with Hurler syndrome appear normal at birth and develop the characteristic appearance over the first years of life. Symptoms across the types include facial dysmorphism, corneal clouding, hepatomegaly, valvular heart disease, obstructive airway disease, developmental delay, hearing loss, skeletal deformities,[4] and joint stiffness. For patients with the more severe form of the disease, the most typical symptoms occur early in life. These patients typically have numerous progressively debilitating symptoms, including mental retardation. Their lifespan is less than 10 years. Individualswithlesssevere disease can have some of thesame physicalsymptoms but generally retain normal intellect and stature, and may have a normallifespan.
The most severe presentation at the other end of the disease spectrum is Hurler syndrome (MPS IH), which is outlined below. These characteristic features in children with the more severe form of MPS I can be less obvious in children with less severe forms of MPS I.
Facial dysmorphism or coarsened facial features
Coarsening of the facial features is usually the first abnormality detected. These features often first become apparent at age 3-6 months and may become progressively more evident. The head is large with bulging frontal bones. The skull is often scaphocephalic secondary to premature closure of the metopic and sagittal sutures. The nasal bridge is depressed with broad nasal tip and anteverted nostrils. The cheeks are full. The lips are enlarged, and the mouth is usually held open, particularly after age 3 years. Chronic nasal discharge is present. Eyes may be widely spaced, and eye sockets may be shallow, causing the eyes to slightly protrude.
The clinical presentation in less severe disease (MPS IS) may be limited to mild coarsening of facial features and prognathism. A large mouth with thick lips may develop.
Corneal clouding
As a result of glycosaminoglycan (GAG) storage, progressive corneal clouding is common in MPS I and can begin as early as the first year of life. Clouding of the cornea has a ground-glass appearance and may lead to blindness. Retinal degeneration is also common in MPS I.
Visceral involvement
Progressive hepatosplenomegaly is common in MPS I. GAG storage in the liver and spleen does not lead to organ dysfunction; however, organ size may be massive. Loose stools and diarrhea are episodic problems for some patients. Inguinal and umbilical hernias are common in MPS I. They are occasionally present at birth or develop within the first several months of life and are often one of the first clinical signs noted.
Skeletal involvement
Patients with severe disease demonstrate skeletal manifestations of MPS I early in life, by about age 6 months. At that time, widening of the ribs and mild bone abnormalities (detected by radiological methods) are common, particularly within the hip and ovoid vertebrae. At the clinical level, skeletal involvement does not become obvious until age 10-14 months, when a gibbus deformity of the back, or dorsolumbar kyphosis, is observed in patients with severe disease.
Eventually, progressive skeletal dysplasia involving all bones is seen in all types of MPS. The vertebrae may become progressively flattened and beaked, often leading to spinal deformity. Typically, the pelvis is poorly formed, with small femoral heads and coxa valga. Involvement of the femoral head leads to progressive and debilitating hip deformity. Clavicles may be short, thickened, and irregular (“oar-shaped”).
Length is often normal until about age 2 years, when growth stops; by age 3 years, height is less than the third percentile, and children may not grow taller than 4 ft.
Joint stiffness
The joints may become stiffened by age 2 years, and progressive arthropathy affects all joints. The hands take on a characteristic claw deformity, resulting from both phalangeal dysostosis and synovial thickening.
Carpal tunnel syndrome, a common complication in the MPSs, probably results from a combination of excessive lysosomal storage in the connective tissue of the flexor retinaculum and a deformity secondary to the underlying skeletal dysplasia.
Cardiopulmonary
Valvular disease, specifically aortic valve disease, may be seen in these patients. Frequent upper and lower respiratory tract infections are common. Respiratory obstruction occurs secondary to enlargement of tonsils and adenoids, chronic hearing loss, and enlarged tongue. However, in mild forms, the intellectual level is normal.
Development
In severe forms of MPS I, developmental delay is often apparent by age 12-24 months, with a maximum functional age of 2-4 years, followed by progressive deterioration. Most children develop limited language because of developmental delay.
Others
The neck is short, and odontoid hypoplasia is noted. Vertebral subluxation with cord compression can occur. Body hair may be coarser than usual, and the skin may be thicker.
Causes
Mucopolysaccharidosis type I (MPS I) is caused by a deficiency of the lysosomal enzyme, a-L-iduronidase.[5] This deficiency leads to accumulation of undegraded mucopolysaccharides, especially dermatan sulfate, in tissues and organs. The buildup of excess dermatan sulfate (DS) leads to the gradual development of numerous morphological abnormalities in tissues and organs. The a-L-iduronidase gene has been mapped to chromosome band 4p16.3. The metabolic defect in MPS IH has an autosomal recessive mode of inheritance.
Yano S, Moseley K, Pavlova Z. Postmortem studies on a patient with mucopolysaccharidosis type I: Histopathological findings after one year of enzyme replacement therapy. J Inherit Metab Dis. Mar 27 2009;[Medline].
Moore D, Connock MJ, Wraith E, Lavery C. The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK. Orphanet J Rare Dis. Sep 16 2008;3:24. [Medline].
D'Aco K, Underhill L, Rangachari L, Arn P, Cox GF, Giugliani R, et al. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry. Eur J Pediatr. Jan 11 2012;[Medline].
Pastores GM. Musculoskeletal complications encountered in the lysosomal storage disorders. Best Pract Res Clin Rheumatol. Oct 2008;22(5):937-47. [Medline].
Müller KB, Pereira VG, Martins AM, D'Almeida V. Evaluation of a-iduronidase in dried blood spots is an accurate tool for mucopolysaccharidosis I diagnosis. J Clin Lab Anal. 2011;25(4):251-4. [Medline].
Cunningham M, Cox EO. Hearing assessment in infants and children: recommendations beyond neonatal screening. Pediatrics. Feb 2003;111(2):436-40. [Medline].
Muenzer J, Wraith JE, Clarke LA. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. Jan 2009;123(1):19-29. [Medline].
Clarke LA, Wraith JE, Beck M, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. Jan 2009;123(1):229-40. [Medline].
Giugliani R, Rojas VM, Martins AM, et al. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Mol Genet Metab. Jan 2009;96(1):13-9. [Medline].
Pastores GM. Laronidase (Aldurazyme): enzyme replacement therapy for mucopolysaccharidosis type I. Expert Opin Biol Ther. Jul 2008;8(7):1003-9. [Medline].
de Ru MH, Boelens JJ, Das AM, Jones SA, van der Lee JH, Mahlaoui N, et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis. Aug 10 2011;6:55. [Medline]. [Full Text].
Arn P, Wraith JE, Underhill L. Characterization of Surgical Procedures in Patients with Mucopolysaccharidosis Type I: Findings from the MPS I Registry. J Pediatr. Feb 11 2009;[Medline].
Herrero R, Brinton LA, Reeves WC, Brenes MM, de Britton RC, Tenorio F, et al. Injectable contraceptives and risk of invasive cervical cancer: evidence of an association. Int J Cancer. Jul 15 1990;46(1):5-7. [Medline].
Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly W, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. Vol 3. 8th ed. New York, NY: McGraw Hill; 2001:3421-52.
Print
